News | April 12, 2025
Morepen to add 1,000 medical representatives
The company is targeting a Rs. 1,000 crore finished dosages business within the next five years
The company is targeting a Rs. 1,000 crore finished dosages business within the next five years
Shilpa’s product has been approved as a generic version to the innovator - Chantix Tablets, 0.5 mg and 1 mg, of PF Prism C.V. (PF Prism)
Mantri will replace V. S. Mani, Executive Director & Global Chief Financial Officer of the company as he has conveyed his decision to opt for early retirement
NATCO has decided to price the product at Rs.15, 900 MRP consistent with the company’s stand before the court
Introduces revolutionary approach to workflow management to enhance operational efficiency and optimize process efficiency
Dr Reddy’s said scheme of amalgamation was carried with adherence to all the legal requirements including tax laws
In light of the contributions of these three institutes, it was decided to organize a CSIR Startup Conclave in Hyderabad. The event, scheduled for April 22–23, 2025
Findings likely to generate hypotheses about potential new uses of drugs
The portfolio includes branded injectable cephalosporines for infectious diseases
Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone
Subscribe To Our Newsletter & Stay Updated
